ON101 Emerging Drug Insight

“ON101 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about ON101 for chronic wounds in the six major markets. A detailed picture of the ON101 for chronic wounds in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this report along with a detailed description of the ON101 for chronic wounds. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ON101 market forecast analysis for chronic wounds in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic wounds.

Drug Summary

ON101 is a new botanical drug ointment that possesses the function of diabetic wound healing and high safety. The main mechanisms of ON101 are to reduce wound inflammation, increase epithelialization of the epidermal tissues, promote collagen production, and decrease granulation tissue development in the wound. The active pharmaceutical ingredient (API) of ON101 is composed of extracts from two commonly used traditional Chinese herbal medicine, Plectranthus amboinicus, and the Centella asiatica.

It is a first-in-class drug targeting the subsets of macrophages to promote the healing of chronic wounds. It has been demonstrated with superior efficacy to the standard care dressing in a Phase III MRCT completed in the US, Taiwan, and China. It has been marketed under the trade name FESPIXON in Taiwan since June 2021.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ON101 description, mechanism of action, dosage and administration, research and development activities in chronic wounds.
• Elaborated details on ON101 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ON101 research and development activities in chronic wounds across the United States and Europe.
• The report also covers the patents information with expiry timeline around ON101.
• The report contains forecasted sales of for chronic wounds till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic wounds.
• The report also features the SWOT analysis with analyst views for ON101 in chronic wounds.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ON101 Analytical Perspective by DelveInsight

• In-depth ON101 Market Assessment

This report provides a detailed market assessment of ON101 for chronic wounds in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2025 to 2032.

• ON101 Clinical Assessment

The report provides the clinical trials information of ON101 for chronic wounds covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic wounds is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ON101 dominance.
• Other emerging products for chronic wounds are expected to give tough market competition to ON101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ON101 in chronic wounds.
• Our in-depth analysis of the forecasted sales data of ON101 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ON101 in chronic wounds.
•  

Key Questions

• What is the product type, route of administration and mechanism of action of ON101?
• What is the clinical trial status of the study related to ON101 in chronic wounds and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ON101 development?
• What are the key designations that have been granted to ON101 for chronic wounds?
• What is the forecasted market scenario of ON101 for chronic wounds?
• What are the forecasted sales of ON101 in the six major countries, including the United States and Europe (Germany, France, Italy, Spain, and the United Kingdom)? 
• What are the other emerging products available and how are these giving competition to ON101 for chronic wounds?
• Which are the late-stage emerging therapies under development for the treatment of chronic wounds?